Two-Dimensional Regulation of CAR-T Cell Therapy with Orthogonal Switches

Davila, 2014, Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia, Sci. Transl. Med., 6, 224ra25, 10.1126/scitranslmed.3008226 Turtle, 2016, CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients, J. Clin. Invest., 126, 2123, 10.1172/JCI85309 Grupp, 2013, Chimeric antigen receptor-modified T cells for acute lymphoid leukemia, N. Engl. J. Med., 368, 1509, 10.1056/NEJMoa1215134 Park, 2018, Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia, N. Engl. J. Med., 378, 449, 10.1056/NEJMoa1709919 Schuster, 2017, Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas, N. Engl. J. Med., 377, 2545, 10.1056/NEJMoa1708566 Neelapu, 2017, Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma, N. Engl. J. Med., 377, 2531, 10.1056/NEJMoa1707447 Berdeja, 2017, Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy, Blood, 130, 740, 10.1182/blood.V130.Suppl_1.740.740 Ahmed, 2015, Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma, J. Clin. Oncol., 33, 1688, 10.1200/JCO.2014.58.0225 Yazdanifar, 2016, Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cells, Curr. Trends Immunol., 17, 95 Sidaway, 2017, Immunotherapy: Glioblastoma regression obtained with CAR T cells, Nat. Rev. Clin. Oncol., 14, 138 Maus, 2016, Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy, Clin. Cancer Res., 22, 1875, 10.1158/1078-0432.CCR-15-1433 Sun, 2015, The quest for spatio-temporal control of CAR T cells, Cell Res., 25, 1281, 10.1038/cr.2015.131 Lim, 2017, The Principles of Engineering Immune Cells to Treat Cancer, Cell, 168, 724, 10.1016/j.cell.2017.01.016 Sadelain, 2013, The basic principles of chimeric antigen receptor design, Cancer Discov., 3, 388, 10.1158/2159-8290.CD-12-0548 Sadelain, 2017, Therapeutic T cell engineering, Nature, 545, 423, 10.1038/nature22395 Zhong, 2010, Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication, Mol. Ther., 18, 413, 10.1038/mt.2009.210 Foster, 2017, Regulated Expansion and Survival of Chimeric Antigen Receptor-Modified T Cells Using Small Molecule-Dependent Inducible MyD88/CD40, Mol. Ther., 25, 2176, 10.1016/j.ymthe.2017.06.014 Lyddane, 2006, Cutting Edge: CD28 controls dominant regulatory T cell activity during active immunization, J. Immunol., 176, 3306, 10.4049/jimmunol.176.6.3306 Milone, 2009, Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo, Mol. Ther., 17, 1453, 10.1038/mt.2009.83 Kalos, 2011, T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia, Sci. Transl. Med., 3, 95ra73, 10.1126/scitranslmed.3002842 Maude, 2014, Chimeric antigen receptor T cells for sustained remissions in leukemia, N. Engl. J. Med., 371, 1507, 10.1056/NEJMoa1407222 Narayanan, 2011, A composite MyD88/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy, J. Clin. Invest., 121, 1524, 10.1172/JCI44327 Mata, 2017, Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models, Cancer Discov., 7, 1306, 10.1158/2159-8290.CD-17-0263 Spencer, 1993, Controlling signal transduction with synthetic ligands, Science, 262, 1019, 10.1126/science.7694365 Clackson, 1998, Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity, Proc. Natl. Acad. Sci. USA, 95, 10437, 10.1073/pnas.95.18.10437 Kemnade, 2012, Off-the-shelf adenoviral-mediated immunotherapy via bicistronic expression of tumor antigen and iMyD88/CD40 adjuvant, Mol. Ther., 20, 1462, 10.1038/mt.2012.48 Di Stasi, 2011, Inducible apoptosis as a safety switch for adoptive cell therapy, N. Engl. J. Med., 365, 1673, 10.1056/NEJMoa1106152 Spencer, 1996, Functional analysis of Fas signaling in vivo using synthetic inducers of dimerization, Curr. Biol., 6, 839, 10.1016/S0960-9822(02)00607-3 Straathof, 2005, An inducible caspase 9 safety switch for T-cell therapy, Blood, 105, 4247, 10.1182/blood-2004-11-4564 Zhou, 2014, Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene, Blood, 123, 3895, 10.1182/blood-2014-01-551671 Diaconu, 2017, Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells, Mol. Ther., 25, 580, 10.1016/j.ymthe.2017.01.011 Fan, 1999, Improved artificial death switches based on caspases and FADD, Hum. Gene Ther., 10, 2273, 10.1089/10430349950016924 Sabatini, 1994, RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs, Cell, 78, 35, 10.1016/0092-8674(94)90570-3 Brown, 1994, A mammalian protein targeted by G1-arresting rapamycin-receptor complex, Nature, 369, 756, 10.1038/369756a0 Kunz, 1993, Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression, Cell, 73, 585, 10.1016/0092-8674(93)90144-F Chen, 1995, Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue, Proc. Natl. Acad. Sci. USA, 92, 4947, 10.1073/pnas.92.11.4947 Ho, 1996, Dimeric ligands define a role for transcriptional activation domains in reinitiation, Nature, 382, 822, 10.1038/382822a0 Bayle, 2006, Rapamycin analogs with differential binding specificity permit orthogonal control of protein activity, Chem. Biol., 13, 99, 10.1016/j.chembiol.2005.10.017 Rivera, 1996, A humanized system for pharmacologic control of gene expression, Nat. Med., 2, 1028, 10.1038/nm0996-1028 Stankunas, 2003, Conditional protein alleles using knockin mice and a chemical inducer of dimerization, Mol. Cell, 12, 1615, 10.1016/S1097-2765(03)00491-X Stankunas, 2007, Rescue of degradation-prone mutants of the FK506-rapamycin binding (FRB) protein with chemical ligands, ChemBioChem, 8, 1162, 10.1002/cbic.200700087 Shultz, 2005, Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells, J. Immunol., 174, 6477, 10.4049/jimmunol.174.10.6477 Iuliucci, 2001, Intravenous safety and pharmacokinetics of a novel dimerizer drug, AP1903, in healthy volunteers, J. Clin. Pharmacol., 41, 870, 10.1177/00912700122010771 O’Rourke, 2017, A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma, Sci. Transl. Med., 9, eaaa0984, 10.1126/scitranslmed.aaa0984 Morello, 2016, Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors, Cancer Discov., 6, 133, 10.1158/2159-8290.CD-15-0583 Heczey, 2017, CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma, Mol. Ther., 25, 2214, 10.1016/j.ymthe.2017.05.012 Louis, 2011, Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma, Blood, 118, 6050, 10.1182/blood-2011-05-354449 Tey, 2007, Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation, Biol. Blood Marrow Transplant., 13, 913, 10.1016/j.bbmt.2007.04.005 Knochelmann, 2018, CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies, Front. Immunol., 9, 1740, 10.3389/fimmu.2018.01740 Jones, 2014, Improving the safety of cell therapy products by suicide gene transfer, Front. Pharmacol., 5, 254, 10.3389/fphar.2014.00254 Philip, 2014, A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy, Blood, 124, 1277, 10.1182/blood-2014-01-545020 Tasian, 2017, Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia, Blood, 129, 2395, 10.1182/blood-2016-08-736041 Stavrou, 2018, A Rapamycin-Activated Caspase 9-Based Suicide Gene, Mol. Ther., 26, 1266, 10.1016/j.ymthe.2018.03.001 Liberles, 1997, Inducible gene expression and protein translocation using nontoxic ligands identified by a mammalian three-hybrid screen, Proc. Natl. Acad. Sci. USA, 94, 7825, 10.1073/pnas.94.15.7825